Cello Health Acquires ISS

NEW YORK, Aug. 19, 2019 /PRNewswire/ — Cello Health has announced further expansion in the United States with the acquisition of New Jersey-based company Innovative Science Solutions, LLC (‘ISS’) on August 15.

ISS is a leading scientific consulting firm founded by Steven Weisman, PhD and David Schwartz, PhD nearly 20 years ago. The company specializes in strategic regulatory support for the healthcare industry and scientific support on health-related issues for legal counsel.

The technical service offering includes consultancy at all stages in the regulatory process, support of FDA Advisory Committee meetings, and data provision in legal defense of patent and intellectual property issues. Clients are predominantly US based, though the company also supports ex-US based clients with relevant needs in the US market.

Stephen Highley, Chairman of Cello Health, commented: “We are very pleased to welcome ISS to Cello Health. Consistent with Cello Health, ISS has achieved a strong reputation for provision of its scientific consulting services, and the specificity of these technical services is a perfect addition to Cello’s focus on supporting client’s along the most critical drug development and successful commercialization pathways.”

“The acquisition of ISS is an excellent strategic fit as we continue our expansion in the US,” added Julia Ralston, CEO, Cello Health US. “We are excited about how the clear synergies between this new offer and our existing capabilities will benefit Cello Health’s clients and our work tackling their biggest challenges in navigating scientific, commercial, and regulatory approaches that increase an asset’s market potential.”

About Cello Health

Navigating Complexity > Steering Decisions > Building Solutions

Cello Health is a thought-leading health advisory firm, with experts in science, insight, strategy and communications. We are able to respond to our client’s most complex challenges through a fusion of this expertise or as a specialist service within the capabilities of:

  • Business Insights and Analytics
  • Strategic and Scientific Consultancy
  • Scientific and Creative Communications

In the pursuit of better, Cello Health therefore builds bold solutions and makes insightful recommendations to help clients deliver medicines and innovations that have a remarkable impact on people’s lives.

For further media information, please visit www.cellohealth.com

 

View original content:http://www.prnewswire.com/news-releases/cello-health-acquires-iss-300903030.html

SOURCE Cello Health

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

11 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

12 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago